Letters

AANS and CNS Comment on Cost Measures for Movement Disorders

  • Quality Improvement and Patient Safety

Acumen, LLC
500 Airport Blvd. Suite 365
Burlingame, CA 94010

Submitted via macra-clinical-committee-support@acumenllc.com

Subject: 2024 Cost Measure Field Testing-Wave 6 Movement Disorders Cost Measure

To whom it may concern:

On behalf of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), representing more than 4,000 neurosurgeons in the United States, we appreciate the opportunity to provide feedback on the episode-based cost measure currently being field tested titled, “Movement Disorders: Parkinson’s and Related Conditions, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS).”

Click here to read the full AANS and CNS Comment on Cost Measures for Movement Disorders.